1. 1Causes of death, 2000–2016, Global Health Estimates (GHE), World Health Organiation (WHO). https://www.who.int/healt hinfo/global_burden_disease/estimates/en/. Accessed on 3rd October, 2020.
2. Packer, M. et al. Te efect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349–1355 (1996).
3. 3Te Cardiac Insufciency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9–13, (1999).
4. Kotecha, D. et al. Efcacy of beta blockers in patients with heart failure plus atrial fbrillation: an individual-patient data metaanalysis. Lancet 384, 2235–2243 (2014).
5. Metra, M. & Teerlink, J. R. Heart failure. Lancet 390, 1981–1995 (2017).
6. Navarrete, E. G. et al. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 128, S3-13 (2013).
7. Onakpoya, I. J., Heneghan, C. J. & Aronson, J. K. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. Crit. Rev. Toxicol. 46, 477–489 (2016).
8. Lexchin, J. Drug withdrawals from the Canadian market for safety reasons, 1963–2004. CMAJ 172, 765–767 (2005).
9. Cavero, I. & Crumb, W. ICH S7B draf guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin. Drug Saf. 4, 509–530 (2005).
10. Redfern, W. S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32–45 (2003).
11. Liang, P. et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals diseasespecifc patterns of cardiotoxicity. Circulation 127, 1677–1691 (2013).
12. Hino, K. et al. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fbrodysplasia ossifcans progressiva. J. Clin. Invest. 127, 3339–3352 (2017).
13. Kondo, T. et al. iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid beta combination for Alzheimer’s disease. Cell Rep. 21, 2304–2312 (2017).
14. Vicente, J. et al. Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the “CiPA” initiative and design of a prospective clinical validation study. Clin. Pharmacol. Ter. 103, 54–66 (2018).
15. Sallam, K., Li, Y., Sager, P. T., Houser, S. R. & Wu, J. C. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ. Res. 116, 1989–2004 (2015).
16. Kitaguchi, T. et al. CSAHi study: evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia–efects of 7 reference compounds at 10 facilities. J. Pharmacol. Toxicol. Methods 78, 93–102 (2016).
17. Kawatou, M. et al. Modelling Torsade de Pointes arrhythmias in vitro in 3D human iPS cell-engineered heart tissue. Nat. Commun. 8, 1078 (2017).
18. Kim, D. S. et al. Highly durable crack sensor integrated with silicone rubber cantilever for measuring cardiac contractility. Nat. Commun. 11, 535 (2020).
19. Gao, B., Matsuura, K. & Shimizu, T. Recent progress in induced pluripotent stem cell-derived cardiac cell sheets for tissue engineering. Biosci. Trends 13, 292–298 (2019).
20. Sasaki, D. et al. Contractile force measurement of human induced pluripotent stem cell-derived cardiac cell sheet-tissue. PLoS ONE 13, e0198026 (2018).
21. Tanaka, Y. et al. An actuated pump on-chip powered by cultured cardiomyocytes. Lab. Chip 6, 362–368 (2006).
22. Tanaka, Y. et al. A micro-spherical heart pump powered by cultured cardiomyocytes. Lab. Chip 7, 207–212 (2007).
23. Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662–1668 (2010).
24. Masumoto, H. et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci. Rep. 4, 6716 (2014).
25. Masumoto, H. et al. Te myocardial regenerative potential of three-dimensional engineered cardiac tissues composed of multiple human iPS cell-derived cardiovascular cell lineages. Sci. Rep. 6, 29933 (2016).
26. Nakane, T. et al. Impact of cell composition and geometry on human induced pluripotent stem cells-derived engineered cardiac tissue. Sci. Rep. 7, 45641 (2017).
27. Jackman, C. P., Carlson, A. L. & Bursac, N. Dynamic culture yields engineered myocardium with near-adult functional output. Biomaterials 111, 66–79 (2016).
28. Gao, L. et al. Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in swine. Circulation 137, 1712–1730 (2018).
29. Funano, S. I., Ota, N., Sato, A. & Tanaka, Y. A method of packaging molecule/cell-patterns in an open space into a glass microfuidic channel by combining pressure-based low/room temperature bonding and fuorosilane patterning. Chem. Commun. (Camb.) 53, 11193–11196 (2017).
30. Endoh, M. Force-frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur. J. Pharmacol. 500, 73–86 (2004).
31. Yalikun, Y. & Tanaka, Y. Ultra-thin glass sheet integrated transparent diaphragm pressure transducer. Sens. Actuat. A Phys. 263, 102–112 (2017).
32. Tanaka, Y., Noguchi, Y., Yalikun, Y. & Kamamichi, N. Earthworm muscle driven bio-micropump. Sens. Actuat. B-Chem. 242, 1186–1192 (2017).
33. Sala, L. et al. MUSCLEMOTION: a versatile open sofware tool to quantify cardiomyocyte and cardiac muscle contraction in vitro and in vivo. Circ. Res. 122, e5–e16 (2018).
34. Shiba, Y. et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489, 322–325 (2012).
35. Shiba, Y. et al. Electrical integration of human embryonic stem cell-derived cardiomyocytes in a guinea pig chronic infarct model. J. Cardiovasc. Pharmacol. Ter. 19, 368–381 (2014).
36. Ronaldson-Bouchard, K. et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature 556, 239–243 (2018).
37. Liang, P. et al. Patient-specifc and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of Brugada syndrome. J. Am. Coll. Cardiol. 68, 2086–2096 (2016).
38. Kasai-Brunswick, T. H. et al. Generation of patient-specifc induced pluripotent stem cell lines from one patient with Jervell and Lange-Nielsen syndrome, one with type 1 long QT syndrome and two healthy relatives. Stem Cell Res 31, 174–180 (2018).
39. Yazawa, M. et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471, 230–234 (2011).
40. Sequeira, V. & van der Velden, J. Historical perspective on heart function: the Frank-Starling Law. Biophys. Rev. 7, 421–447 (2015).
41. Tsuruyama, S., Matsuura, K., Sakaguchi, K. & Shimizu, T. Pulsatile tubular cardiac tissues fabricated by wrapping human iPS cells-derived cardiomyocyte sheets. Regen Ter 11, 297–305 (2019).
42. Tanaka, Y. & Fujita, H. Fluid driving system for a micropump by diferentiating iPS cells into cardiomyocytes on a tent-like structure. Sens. Actuat. B-Chem. 210, 267–272 (2015).
43. Tanaka, Y., Yanagisawa, Y. & Kitamori, T. Fluid actuation for a bio-micropump powered by previously frozen cardiomyocytes directly seeded on a diagonally stretched thin membrane. Sens. Actuat. B-Chem. 156, 494–498 (2011).
44. Pelouch, V. Molecular aspects of regulation of cardiac contraction. Physiol. Res. 44, 53–60 (1995).
45. Li, M. et al. Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs. J. Pharmacol. Sci. 134, 75–85 (2017).
46. Xi, J. et al. Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J. 24, 2739–2751 (2010).
47. Parikh, S. S. et al. Tyroid and glucocorticoid hormones promote functional T-tubule development in human-induced pluripotent stem cell-derived cardiomyocytes. Circ. Res. 121, 1323–1330 (2017).
48. Mills, R. J. et al. Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. Proc. Natl. Acad. Sci. USA 114, E8372–E8381 (2017).
49. Yang, X. et al. Fatty acids enhance the maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cell Rep. 13, 657–668 (2019).
50. Minagawa, A. et al. Enhancing T cell receptor stability in rejuvenated iPSC-Derived T cells improves their use in cancer immunotherapy. Cell Stem Cell 23, 850–858 (2018).
51. Miyazaki, T., Isobe, T., Nakatsuji, N. & Suemori, H. Efcient adhesion culture of human pluripotent stem cells using Laminin fragments in an uncoated manner. Sci. Rep. 7, 41165 (2017).
52. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).